Improvement of asthma control with beclomethasone extrafine aerosol compared to fluticasone and budesonide
Qvar ® Autohaler ® efficacy on asthma control, assessed with E. Juniper asthma control questionnaire (ACQ), was compared with fluticasone and budesonide. An open randomized study, stratified (2:1) on the intake of long-acting β 2-mimetics (LA β 2), was performed in patients with moderate to severe p...
Gespeichert in:
| Veröffentlicht in: | Respiratory medicine 2005-06, Vol.99 (6), p.770-778 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 778 |
|---|---|
| container_issue | 6 |
| container_start_page | 770 |
| container_title | Respiratory medicine |
| container_volume | 99 |
| creator | Molimard, Mathieu Martinat, Yan Rogeaux, Yves Moyse, Dominique Pello, Jean-Yves Giraud, Violaine |
| description | Qvar
® Autohaler
® efficacy on asthma control, assessed with E. Juniper asthma control questionnaire (ACQ), was compared with fluticasone and budesonide. An open randomized study, stratified (2:1) on the intake of long-acting
β
2-mimetics (LA
β
2), was performed in patients with moderate to severe poorly controlled asthma (defined by at least one nocturnal discomfort in the last 5 days or a mean of 2 puffs of short-acting
β
2-mimetics in the last 7 days or exercise dyspnea) despite treatment with beclomethasone ⩽1000
μg/day (or equivalent). 460 patients received Qvar Autohaler 800
μg/day (
n
=
149
), fluticasone Diskus 1000
μg/day (
n
=
149
) or budesonide Turbuhaler 1600
μg/day (
n
=
162
) during 12 weeks. Asthma control improved in all groups, with no difference between groups. For patients treated with LA
β
2 (
n
=
286
) a significantly greater improvement of the ACQ score was obtained with Qvar Autohaler versus fluticasone (1.0±1.0 vs. 0.6±0.9;
P
=
0.019
), but not versus budesonide (0.9±0.9). Pulmonary function test improvements were similar in the 3 groups. The significant improvement in asthma control in patients receiving LA
β
2 suggests potential advantages for extrafine aerosols as part of anti-inflammatory treatment optimization. |
| doi_str_mv | 10.1016/j.rmed.2004.10.024 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67805442</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0954611104004640</els_id><sourcerecordid>2745060931</sourcerecordid><originalsourceid>FETCH-LOGICAL-c456t-6ca204e272ad7310aaa4a3b847e5d5a3c386279384042ef5cc4b263e568ff8183</originalsourceid><addsrcrecordid>eNp9kU2L1EAQhhtR3HH1D3iQgOgtY3-nA16WZVcXFvaynptKp8J0SNJjd2fVf2-HGRQ8eKqvp4qqegl5y-ieUaY_jfs4Y7_nlMqS2FMun5EdU4LXgmr5nOxoq2StGWMX5FVKI6W0lZK-JBdMmcbIVu3IeDcfY3jCGZdchaGClA8zVC4sOYap-uHzoerQTWHGfIAUFqzwZ44w-OIBxpAK5cJ8hIh9lUM1TGv27kTC0lfd2mMJfI-vyYsBpoRvzvaSfLu9ebz-Wt8_fLm7vrqvnVQ619oBpxJ5w6FvBKMAIEF0RjaoegXCCaN50wojqeQ4KOdkx7VApc0wGGbEJfl4mlsO-75iynb2yeE0wYJhTVY3hiopeQHf_wOOYY1L2c0yKhRVrdSyUPxEuXJsijjYY_QzxF8FspsOdrSbDnbTYcsVHUrTu_Potdtqf1rOjy_AhzMAycE0RFicT3853bSqFRv3-cRh-diTx2iT87g47H1El20f_P_2-A0r9Kct</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1035059464</pqid></control><display><type>article</type><title>Improvement of asthma control with beclomethasone extrafine aerosol compared to fluticasone and budesonide</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Molimard, Mathieu ; Martinat, Yan ; Rogeaux, Yves ; Moyse, Dominique ; Pello, Jean-Yves ; Giraud, Violaine</creator><creatorcontrib>Molimard, Mathieu ; Martinat, Yan ; Rogeaux, Yves ; Moyse, Dominique ; Pello, Jean-Yves ; Giraud, Violaine</creatorcontrib><description>Qvar
® Autohaler
® efficacy on asthma control, assessed with E. Juniper asthma control questionnaire (ACQ), was compared with fluticasone and budesonide. An open randomized study, stratified (2:1) on the intake of long-acting
β
2-mimetics (LA
β
2), was performed in patients with moderate to severe poorly controlled asthma (defined by at least one nocturnal discomfort in the last 5 days or a mean of 2 puffs of short-acting
β
2-mimetics in the last 7 days or exercise dyspnea) despite treatment with beclomethasone ⩽1000
μg/day (or equivalent). 460 patients received Qvar Autohaler 800
μg/day (
n
=
149
), fluticasone Diskus 1000
μg/day (
n
=
149
) or budesonide Turbuhaler 1600
μg/day (
n
=
162
) during 12 weeks. Asthma control improved in all groups, with no difference between groups. For patients treated with LA
β
2 (
n
=
286
) a significantly greater improvement of the ACQ score was obtained with Qvar Autohaler versus fluticasone (1.0±1.0 vs. 0.6±0.9;
P
=
0.019
), but not versus budesonide (0.9±0.9). Pulmonary function test improvements were similar in the 3 groups. The significant improvement in asthma control in patients receiving LA
β
2 suggests potential advantages for extrafine aerosols as part of anti-inflammatory treatment optimization.</description><identifier>ISSN: 0954-6111</identifier><identifier>EISSN: 1532-3064</identifier><identifier>DOI: 10.1016/j.rmed.2004.10.024</identifier><identifier>PMID: 15878495</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Administration, Inhalation ; Adult ; Aerosols ; Albuterol - analogs & derivatives ; Albuterol - therapeutic use ; Androstadienes - therapeutic use ; Anti-Inflammatory Agents - therapeutic use ; Asthma ; Asthma - drug therapy ; Asthma - physiopathology ; Asthma control ; Asthma control questionnaire ; Beclomethasone - administration & dosage ; Beclomethasone - therapeutic use ; Beclomethasone extrafine aerosol ; Biological and medical sciences ; Bronchodilator Agents - therapeutic use ; Budesonide ; Budesonide - therapeutic use ; Chronic obstructive pulmonary disease, asthma ; Compliance ; Drug Administration Schedule ; Drug dosages ; Drug therapy ; Drug Therapy, Combination ; Ethanolamines - therapeutic use ; Evolution ; Female ; Fluticasone ; Formoterol Fumarate ; Humans ; Leukotriene Antagonists - therapeutic use ; Male ; Medical sciences ; Metered Dose Inhalers ; Middle Aged ; Particle Size ; Peak Expiratory Flow Rate ; Pneumology ; Questionnaires ; Respiratory Function Tests ; Salmeterol Xinafoate</subject><ispartof>Respiratory medicine, 2005-06, Vol.99 (6), p.770-778</ispartof><rights>2005 Elsevier Ltd</rights><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c456t-6ca204e272ad7310aaa4a3b847e5d5a3c386279384042ef5cc4b263e568ff8183</citedby><cites>FETCH-LOGICAL-c456t-6ca204e272ad7310aaa4a3b847e5d5a3c386279384042ef5cc4b263e568ff8183</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.rmed.2004.10.024$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,3548,27923,27924,45994</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16795935$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15878495$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Molimard, Mathieu</creatorcontrib><creatorcontrib>Martinat, Yan</creatorcontrib><creatorcontrib>Rogeaux, Yves</creatorcontrib><creatorcontrib>Moyse, Dominique</creatorcontrib><creatorcontrib>Pello, Jean-Yves</creatorcontrib><creatorcontrib>Giraud, Violaine</creatorcontrib><title>Improvement of asthma control with beclomethasone extrafine aerosol compared to fluticasone and budesonide</title><title>Respiratory medicine</title><addtitle>Respir Med</addtitle><description>Qvar
® Autohaler
® efficacy on asthma control, assessed with E. Juniper asthma control questionnaire (ACQ), was compared with fluticasone and budesonide. An open randomized study, stratified (2:1) on the intake of long-acting
β
2-mimetics (LA
β
2), was performed in patients with moderate to severe poorly controlled asthma (defined by at least one nocturnal discomfort in the last 5 days or a mean of 2 puffs of short-acting
β
2-mimetics in the last 7 days or exercise dyspnea) despite treatment with beclomethasone ⩽1000
μg/day (or equivalent). 460 patients received Qvar Autohaler 800
μg/day (
n
=
149
), fluticasone Diskus 1000
μg/day (
n
=
149
) or budesonide Turbuhaler 1600
μg/day (
n
=
162
) during 12 weeks. Asthma control improved in all groups, with no difference between groups. For patients treated with LA
β
2 (
n
=
286
) a significantly greater improvement of the ACQ score was obtained with Qvar Autohaler versus fluticasone (1.0±1.0 vs. 0.6±0.9;
P
=
0.019
), but not versus budesonide (0.9±0.9). Pulmonary function test improvements were similar in the 3 groups. The significant improvement in asthma control in patients receiving LA
β
2 suggests potential advantages for extrafine aerosols as part of anti-inflammatory treatment optimization.</description><subject>Administration, Inhalation</subject><subject>Adult</subject><subject>Aerosols</subject><subject>Albuterol - analogs & derivatives</subject><subject>Albuterol - therapeutic use</subject><subject>Androstadienes - therapeutic use</subject><subject>Anti-Inflammatory Agents - therapeutic use</subject><subject>Asthma</subject><subject>Asthma - drug therapy</subject><subject>Asthma - physiopathology</subject><subject>Asthma control</subject><subject>Asthma control questionnaire</subject><subject>Beclomethasone - administration & dosage</subject><subject>Beclomethasone - therapeutic use</subject><subject>Beclomethasone extrafine aerosol</subject><subject>Biological and medical sciences</subject><subject>Bronchodilator Agents - therapeutic use</subject><subject>Budesonide</subject><subject>Budesonide - therapeutic use</subject><subject>Chronic obstructive pulmonary disease, asthma</subject><subject>Compliance</subject><subject>Drug Administration Schedule</subject><subject>Drug dosages</subject><subject>Drug therapy</subject><subject>Drug Therapy, Combination</subject><subject>Ethanolamines - therapeutic use</subject><subject>Evolution</subject><subject>Female</subject><subject>Fluticasone</subject><subject>Formoterol Fumarate</subject><subject>Humans</subject><subject>Leukotriene Antagonists - therapeutic use</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Metered Dose Inhalers</subject><subject>Middle Aged</subject><subject>Particle Size</subject><subject>Peak Expiratory Flow Rate</subject><subject>Pneumology</subject><subject>Questionnaires</subject><subject>Respiratory Function Tests</subject><subject>Salmeterol Xinafoate</subject><issn>0954-6111</issn><issn>1532-3064</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU2L1EAQhhtR3HH1D3iQgOgtY3-nA16WZVcXFvaynptKp8J0SNJjd2fVf2-HGRQ8eKqvp4qqegl5y-ieUaY_jfs4Y7_nlMqS2FMun5EdU4LXgmr5nOxoq2StGWMX5FVKI6W0lZK-JBdMmcbIVu3IeDcfY3jCGZdchaGClA8zVC4sOYap-uHzoerQTWHGfIAUFqzwZ44w-OIBxpAK5cJ8hIh9lUM1TGv27kTC0lfd2mMJfI-vyYsBpoRvzvaSfLu9ebz-Wt8_fLm7vrqvnVQ619oBpxJ5w6FvBKMAIEF0RjaoegXCCaN50wojqeQ4KOdkx7VApc0wGGbEJfl4mlsO-75iynb2yeE0wYJhTVY3hiopeQHf_wOOYY1L2c0yKhRVrdSyUPxEuXJsijjYY_QzxF8FspsOdrSbDnbTYcsVHUrTu_Potdtqf1rOjy_AhzMAycE0RFicT3853bSqFRv3-cRh-diTx2iT87g47H1El20f_P_2-A0r9Kct</recordid><startdate>20050601</startdate><enddate>20050601</enddate><creator>Molimard, Mathieu</creator><creator>Martinat, Yan</creator><creator>Rogeaux, Yves</creator><creator>Moyse, Dominique</creator><creator>Pello, Jean-Yves</creator><creator>Giraud, Violaine</creator><general>Elsevier Ltd</general><general>Elsevier</general><general>Elsevier Limited</general><scope>6I.</scope><scope>AAFTH</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U9</scope><scope>ASE</scope><scope>FPQ</scope><scope>H94</scope><scope>K6X</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>20050601</creationdate><title>Improvement of asthma control with beclomethasone extrafine aerosol compared to fluticasone and budesonide</title><author>Molimard, Mathieu ; Martinat, Yan ; Rogeaux, Yves ; Moyse, Dominique ; Pello, Jean-Yves ; Giraud, Violaine</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c456t-6ca204e272ad7310aaa4a3b847e5d5a3c386279384042ef5cc4b263e568ff8183</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Administration, Inhalation</topic><topic>Adult</topic><topic>Aerosols</topic><topic>Albuterol - analogs & derivatives</topic><topic>Albuterol - therapeutic use</topic><topic>Androstadienes - therapeutic use</topic><topic>Anti-Inflammatory Agents - therapeutic use</topic><topic>Asthma</topic><topic>Asthma - drug therapy</topic><topic>Asthma - physiopathology</topic><topic>Asthma control</topic><topic>Asthma control questionnaire</topic><topic>Beclomethasone - administration & dosage</topic><topic>Beclomethasone - therapeutic use</topic><topic>Beclomethasone extrafine aerosol</topic><topic>Biological and medical sciences</topic><topic>Bronchodilator Agents - therapeutic use</topic><topic>Budesonide</topic><topic>Budesonide - therapeutic use</topic><topic>Chronic obstructive pulmonary disease, asthma</topic><topic>Compliance</topic><topic>Drug Administration Schedule</topic><topic>Drug dosages</topic><topic>Drug therapy</topic><topic>Drug Therapy, Combination</topic><topic>Ethanolamines - therapeutic use</topic><topic>Evolution</topic><topic>Female</topic><topic>Fluticasone</topic><topic>Formoterol Fumarate</topic><topic>Humans</topic><topic>Leukotriene Antagonists - therapeutic use</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Metered Dose Inhalers</topic><topic>Middle Aged</topic><topic>Particle Size</topic><topic>Peak Expiratory Flow Rate</topic><topic>Pneumology</topic><topic>Questionnaires</topic><topic>Respiratory Function Tests</topic><topic>Salmeterol Xinafoate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Molimard, Mathieu</creatorcontrib><creatorcontrib>Martinat, Yan</creatorcontrib><creatorcontrib>Rogeaux, Yves</creatorcontrib><creatorcontrib>Moyse, Dominique</creatorcontrib><creatorcontrib>Pello, Jean-Yves</creatorcontrib><creatorcontrib>Giraud, Violaine</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Virology and AIDS Abstracts</collection><collection>British Nursing Index</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>British Nursing Index</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Respiratory medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Molimard, Mathieu</au><au>Martinat, Yan</au><au>Rogeaux, Yves</au><au>Moyse, Dominique</au><au>Pello, Jean-Yves</au><au>Giraud, Violaine</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Improvement of asthma control with beclomethasone extrafine aerosol compared to fluticasone and budesonide</atitle><jtitle>Respiratory medicine</jtitle><addtitle>Respir Med</addtitle><date>2005-06-01</date><risdate>2005</risdate><volume>99</volume><issue>6</issue><spage>770</spage><epage>778</epage><pages>770-778</pages><issn>0954-6111</issn><eissn>1532-3064</eissn><abstract>Qvar
® Autohaler
® efficacy on asthma control, assessed with E. Juniper asthma control questionnaire (ACQ), was compared with fluticasone and budesonide. An open randomized study, stratified (2:1) on the intake of long-acting
β
2-mimetics (LA
β
2), was performed in patients with moderate to severe poorly controlled asthma (defined by at least one nocturnal discomfort in the last 5 days or a mean of 2 puffs of short-acting
β
2-mimetics in the last 7 days or exercise dyspnea) despite treatment with beclomethasone ⩽1000
μg/day (or equivalent). 460 patients received Qvar Autohaler 800
μg/day (
n
=
149
), fluticasone Diskus 1000
μg/day (
n
=
149
) or budesonide Turbuhaler 1600
μg/day (
n
=
162
) during 12 weeks. Asthma control improved in all groups, with no difference between groups. For patients treated with LA
β
2 (
n
=
286
) a significantly greater improvement of the ACQ score was obtained with Qvar Autohaler versus fluticasone (1.0±1.0 vs. 0.6±0.9;
P
=
0.019
), but not versus budesonide (0.9±0.9). Pulmonary function test improvements were similar in the 3 groups. The significant improvement in asthma control in patients receiving LA
β
2 suggests potential advantages for extrafine aerosols as part of anti-inflammatory treatment optimization.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>15878495</pmid><doi>10.1016/j.rmed.2004.10.024</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0954-6111 |
| ispartof | Respiratory medicine, 2005-06, Vol.99 (6), p.770-778 |
| issn | 0954-6111 1532-3064 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67805442 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present); EZB-FREE-00999 freely available EZB journals |
| subjects | Administration, Inhalation Adult Aerosols Albuterol - analogs & derivatives Albuterol - therapeutic use Androstadienes - therapeutic use Anti-Inflammatory Agents - therapeutic use Asthma Asthma - drug therapy Asthma - physiopathology Asthma control Asthma control questionnaire Beclomethasone - administration & dosage Beclomethasone - therapeutic use Beclomethasone extrafine aerosol Biological and medical sciences Bronchodilator Agents - therapeutic use Budesonide Budesonide - therapeutic use Chronic obstructive pulmonary disease, asthma Compliance Drug Administration Schedule Drug dosages Drug therapy Drug Therapy, Combination Ethanolamines - therapeutic use Evolution Female Fluticasone Formoterol Fumarate Humans Leukotriene Antagonists - therapeutic use Male Medical sciences Metered Dose Inhalers Middle Aged Particle Size Peak Expiratory Flow Rate Pneumology Questionnaires Respiratory Function Tests Salmeterol Xinafoate |
| title | Improvement of asthma control with beclomethasone extrafine aerosol compared to fluticasone and budesonide |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T13%3A51%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Improvement%20of%20asthma%20control%20with%20beclomethasone%20extrafine%20aerosol%20compared%20to%20fluticasone%20and%20budesonide&rft.jtitle=Respiratory%20medicine&rft.au=Molimard,%20Mathieu&rft.date=2005-06-01&rft.volume=99&rft.issue=6&rft.spage=770&rft.epage=778&rft.pages=770-778&rft.issn=0954-6111&rft.eissn=1532-3064&rft_id=info:doi/10.1016/j.rmed.2004.10.024&rft_dat=%3Cproquest_cross%3E2745060931%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1035059464&rft_id=info:pmid/15878495&rft_els_id=S0954611104004640&rfr_iscdi=true |